Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2013

View Archived Issues

Proteologics and Newcastle Innovation enter exclusive agreement

GPBB as a novel plasma biomarker for ischemic stroke

Japanese MHLW approves use of triple therapy with proton pump inhibitors for new indication

AT2 receptor agonist prevents ischemic brain damage after stroke

Gemzar approved for recurrent or refractory malignant lymphoma in Japan

New ERK inhibitors patented by Array BioPharma and Genentech

IMPACT Therapeutics presents new hedgehog inhibitors

Chinese group divulges new protein kinase inhibitors for cancer

Canadian university researchers synthesize novel inhibitors of ABHD6

New tyrosine-protein kinase inhibitors designed by Chinese researchers

Eisai transfers U.S. rights to Targretin

Adasuve receives European marketing authorization

First patient treated in G-202 phase II trial

FDA recommends phase III Androxal studies to be completed as planned

Phase III trial of Lyrica for partial onset seizures meets primary endpoint

Relypsa enrolls first patient in pivotal phase III patiromer trial

UCB and ConfometRx form multitarget R&D partnership

Organovo and ZenBio to create living 3D tissue models

PLX cells given FDA orphan drug status for aplastic anemia

Efficacy of velaglucerase alfa treatment evaluated over 7 years

Otsuka set to launch Neupro Patch in Japan

Genz-682452 shows potential as adjuvant therapy for Fabry disease

Janssen submits application for approval of simeprevir in Japan

New formulation of Afinitor now available in Japan

GlaxoSmithKline launches antimalarial combination tablet in Japan

CCL23 as a novel blood biomarker of brain damage

Alfresa Pharma launches Choreazine in Japan

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...